ArticleJournal of pharmacy & bioallied sciences2025
Comparison of Efficacy and Safety of Single Versus Combination Dmard Therapy in Rheumatoid Arthritis-A Prospective Observational Study.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes joint inflammation and disability if untreated. Disease-modifying anti-rheumatic drugs (DMARDs), including conventional synthetic DMARDs (csDMARDs), biologics (bDMARDs), and targeted synthetic DMARDs (tsDMARDs), play a critical role in managing the disease. Aim: This study aimed to compare the clinical efficacy and safety profiles of single DMARD therapy versus combination DMARD therapy, including biologics and corticosteroids, in RA patients. Materials and methods: 120 adult patients diagnosed with RA were enrolled and divided into two groups: the Single DMARD Therapy Group ( Result and conclusion: Both groups showed significant improvements in disease activity and functional outcomes over DAS28, VAS, and HAQ scores over time. However, the Combination Therapy Group had slightly greater improvements in pain and disability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.